Clinical Trial Update: The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cannabigerol for attention-deficit/hyperactivity disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Cannabigerol (cannabigerol)

Snippet

Sponsor: University of Arkansas, Fayetteville | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 2 | Status: RECRUITING